Current Patent Status

U.S. Method-of-Use Patent Granted (December 2023)

A method-of-use patent has been granted for the treatment of autism spectrum disorder (ASD) using ethosuximide.
This patent covers the clinical application of ethosuximide for improving expressive language and communication abilities in individuals with ASD.

International Patent Filings

International patent applications for ethosuximide-based therapies have been submitted in the European Union, Canada, Mexico, Israel, Australia, and Japan. These filings are currently under review in their respective regions.

Provisional Patents for Enantiomers

AMS Therapeutics LLC has filed provisional patents for novel enantiomeric forms of ethosuximide.

Excerpt from Published Patent:

Abstract

“A pharmacological method for treating the expressive language deficit in an autistic human child or adult is provided. A therapeutically effective dose of a succinimide anticonvulsant, e.g., ethosuximide, methsuximide, phensuximide, or a pharmaceutically acceptable salt thereof, is administered to a patient suffering from expressive language deficit, preferable over an extended period, e.g., six months or longer. Language gains are retained even after treatment is discontinued.“